Request Demo

Last update 19 Apr 2025

Exenatide

Last update 19 Apr 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Exenatide (JAN/USAN/INN), EXENATIDE SYNTHETIC, Exendin-4

+ [20]

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic DiseaseRespiratory Diseases

Active Indication

Diabetes Mellitus, Type 2Diabetes MellitusHypertension, Pulmonary

Inactive Indication

Coronary Artery DiseaseDiabetes ComplicationsDiabetes Mellitus, Type 1+ [12]

Originator Organization

Eli Lilly & Co.

Amylin Pharmaceuticals, Inc.

Active Organization

Aerami Therapeutics, Inc.

Icure Pharmaceutical Inc.Eli Lilly Nederland BV

+ [3]

Inactive Organization

AstraZeneca PLC

Eli Lilly & Co.

Intarcia Therapeutics, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

United States (28 Apr 2005),

Diabetes Mellitus, Type 2

RegulationOrphan Drug (European Union)

Structure/Sequence

Sequence Code 751

Source: *****

355

Clinical Trials associated with Exenatide

CTIS2024-519014-31-00

/ RecruitingPhase 1IIT

- CHDR2418

Start Date12 Mar 2025

Sponsor / Collaborator

Centre for Human Drug Research

NCT02586831

/ WithdrawnPhase 1/2IIT

A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Low Dose Interleukin-2 (IL-2), Adalimumab and Exenatide in the Treatment of New-Onset Type 1 Diabetes

To assess whether there is a difference in endogenous insulin secretion, measured as stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance test), at the 1 year visit, for study subjects receiving combinational therapy versus those receiving placebo. The study will also examine the effect of the proposed treatments on immunological outcomes, specifically proportion of regulatory T cells at the 1 year visit.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Miami

[+1]

NCT05663515

/ RecruitingNot Applicable

EXCEED - A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other non-glucagon like peptide 1 receptor agonists (GLP-1 RA) based glucose lowering drugs (GLDs). Study data will be collected from secondary data sources across 7 European countries. The study will be conducted as a multi-country, long-term, retrospective, observational database study. Initiators of exenatide will be matched to initiators of non-GLP-1 RA based GLDs (comparator group) based on propensity score and calendar period of study entry. All analyses for pancreatic cancer will be conducted in the matched study population using an "intention-to-treat" approach. The study will use information from 8 data sources in 7 European countries (France, Spain, The United Kingdom, Finland, Denmark, Norway, and Sweden). Patients with T2DM, aged 18 years or older, who initiated treatment with exenatide or non-GLP-1 RA based GLDs during the study period, 2006 to 2023, will be included. Exposure to exenatide and non-GLP-1 RA based GLDs will be ascertained from recordings of prescriptions or insurance claims registrations as available in the different data sources. The outcome of pancreatic cancer will be defined as a primary diagnosis of pancreatic cancer during follow-up

Start Date30 Sep 2024

Sponsor / Collaborator

AstraZeneca PLC

[+1]

100 Clinical Results associated with Exenatide

100 Translational Medicine associated with Exenatide

100 Patents (Medical) associated with Exenatide

4,391

Literatures (Medical) associated with Exenatide

01 Jul 2025·NEUROPHARMACOLOGY

Exogenous oral application of PYY and exendin-4 impacts upon taste-related behavior and taste perception in wild-type mice

Article

Author: Dotson, Cedrick D ; Iyer, Satya ; Montmayeur, Jean-Pierre ; Zolotukhin, Sergei

Several gut peptides have been implicated in feeding and body mass accumulation. Glucagon-like peptide 1 (GLP-1) and peptide tyrosine-tyrosine (PYY) have been shown to mediate satiety and reduce food intake. While systemic administration of such peptides has been explored as a therapy for metabolic disease, the effects of these hormones on taste signaling should also be considered given the importance of taste to feeding decisions and considering the fact that components of these signaling systems are expressed in cells of the peripheral gustatory system. We previously demonstrated that genetic disruption of PYY signaling in mice can impact on taste responsiveness and feeding and that viral expression of PYY in the salivary glands of PYY knockout mice can rescue responsiveness. The present work uses adeno-associated virus-mediated salivary gland treatment with both GLP-1 receptor agonist exendin-4 and/or PYY encoding vectors to explore the effect of stimulating these orally present signaling systems on taste-related behavioral responsiveness in male wild-type mice with intact peptide signaling systems. Results showed a significant effect of salivary gland treatment on responsiveness to multiple taste qualities. Data gathered from taste bud cells in vitro suggest that these peptides directly influence the responsiveness of these primary sensory cells. Collectively, these findings show that taste perception can be modulated by the exogenous application of satiety peptides in wild-type mice and suggest that the taste bud is a promising substrate for food intake modulation.

01 May 2025·DIABETES RESEARCH AND CLINICAL PRACTICE

Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis

Article

Author: Holman, Rury R ; Maddaloni, Ernesto ; Coleman, Ruth L

AIMS:

We investigated bone fracture predictors in people with T2D enrolled in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) and evaluated the effects of once-weekly exenatide (EQW) on incident bone fractures.

METHODS:

EXSCEL randomised 14,752 people to EQW 2 mg or placebo with a median follow-up of 3.2 years. In this post-hoc analysis, baseline features associated with incident bone fractures were evaluated with multivariable Cox proportional hazard regression models, accounting for age and sex as confounders. Incidence rates were compared between study arms, and time-to-event analyses performed using Cox-proportional hazard models.

RESULTS:

The primary outcome occurred in 168 (1.1 %) participants. The presence of neuropathy at baseline was associated with a 50 % higher risk (hazard ratio [HR] 1.50, 95 % confidence interval [CI] 1.10-2.05, P = 0.010) of incident bone fractures, while taking metformin at baseline was associated with a 47 % lower risk (HR 0.53, 95 %CI 0.39-0.73, P < 0.001). Incidence rates of bone fractures were similar in the EQW group and in the placebo group (HR 1.11, 95 %CI 0.82-1.51, P = 0.49).

CONCLUSIONS:

Bone fractures in people with T2D occur more frequently in those with diabetic neuropathy, but less frequently in those taking metformin. No evidence was seen of any impact of EQW treatment on bone fractures.

01 Apr 2025·Journal of Drugs in Dermatology

A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies

Article

Author: Shamaei Zadeh, Parisa ; Waggett, Stephanie ; Sagut, Pelin ; Daniel, Sophia ; Stegura, Carol ; Marcelletti, Anthony ; Wine Lee, Lara ; Lyles, Elliott

Glucagon-like peptide-1 (GLP-1) agonists are used to treat type 2 diabetes mellitus (T2DM) and have recently gained approval and popularity for treating obesity and weight loss. There is a lack of data evaluating the types of reactions associated with this medication class, and this study aimed to characterize the types of cutaneous reactions seen across different GLP-1 agonists, and whether differences exist in reactions based on the reason for medication use. Through a retrospective review of cutaneous adverse events associated with semaglutide, dulaglutide, tirzepatide, lixisenatide, liraglutide, and exenatide in the FDA Adverse Event Reporting System, it was found that the 5 most common cutaneous reactions associated with GLP-1 agonists were eczematous, pruritus, drug eruptions, hyperhidrosis, and alopecia. Life-threatening cutaneous adverse events accounted for 2.17% of all cutaneous reactions, with no statistically significant differences observed between drug types. It was also found that GLP-1 agonist use for T2DM exhibited significantly higher rates of alopecia (P=0.000) and hyperhidrosis (P=0.000) in comparison to use for weight management. J Drugs Dermatol. 2025;24(4):413-415. doi:10.36849/JDD.8605.

121

News (Medical) associated with Exenatide

28 Mar 2025

·www.globenewswire.com

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

NanoPortal™ technology successfully delivers semaglutide, the active ingredient in Ozempic®/Wegovy®, in a preclinical study with NPM-139 (semaglutide implant) NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in development for chronic weight management designed to guarantee medication adherence and potentially improve treatment tolerability by providing smooth and steady delivery of GLP-1 therapy March 26, 2025 -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced promising preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight individuals. These results reinforce the company’s commitment to addressing chronic weight management and other chronic diseases by leveraging its proprietary NanoPortal™ implant technology which is designed to enable smooth and steady delivery of therapeutic molecules including GLP-1 therapy. This development marks a significant advancement in improving medication adherence and patient convenience, addressing a critical gap in the treatment of chronic diseases including obesity and type 2 diabetes. “Products containing semaglutide generated $25 billion in 2024 and demand for these products continues to soar. Since over half of these patients regularly miss doses as indicated by real-world medication adherence data, we believe that there is a tremendous opportunity for a more convenient delivery option that will eliminate missed doses and thereby improve real-world health outcomes. We continue to believe that the primary expected advantages of our proprietary NanoPortal implant technology, improving medication adherence and medication tolerability, have the potential to transform and expand the adoption of GLP-1 therapy in the future,” said Adam Mendelsohn, Ph.D., Vivani Medical’s Chief Executive Officer. “This preclinical demonstration of NPM-139 comes on the heels of having rapidly enrolled and successfully implanted an initial group of subjects in LIBERATE-1, our first-in-human study with NPM-115, which we expect will pave the road for NPM-139 as development continues for both programs.” In an ongoing study in healthy rats, a single administration of the semaglutide implant NPM-139 resulted in body weights that were nearly 20% lower than a sham implant control group throughout a 91-day treatment period. Like NPM-119 and NPM-115, NPM-139 has demonstrated smooth, non-fluctuating in vivo release; this was confirmed by pharmacokinetic data from this study which demonstrated continuous and steady semaglutide exposure throughout the study period. NPM-139 has previously demonstrated therapeutic semaglutide exposure levels in pharmacokinetic data over a six-month duration in healthy rats. In vitro chemical and physical stability measurements for durations exceeding one year indicate the potential for once-yearly administration of NPM-139. Together, these data demonstrate the versatility of the NanoPortal technology beyond NPM-115 (exenatide implant) and provide significant encouragement for continued development of each program. The ongoing NPM-115 clinical study, LIBERATE-1, for which the first successful implantation was recently announced, remains on track to produce top-line data by mid-2025. While LIBERATE-1 will primarily inform continued development of NPM-115, LIBERATE-1 will also provide critical information to support the development of NPM-139 and other pipeline programs since it represents the first human application of the NanoPortal technology. LIBERATE-1 is a Phase 1, first-in-human study of a miniature, ultra long-acting GLP-1 (exenatide) implant, NPM-115, to investigate the safety, tolerability, and full pharmacokinetic profile in obese or overweight subjects. The trial has enrolled participants who are intended to be titrated on weekly semaglutide injections for 8 weeks (0.25 mg/week for 4 weeks followed by 0.5 mg/week for 4 weeks) before being randomized to receive a single administration of Vivani’s exenatide implant (NPM-115, n=8), weekly exenatide injections (Bydureon BCise®, n=8), or weekly 1 mg semaglutide injections (Wegovy®, n=8) for a 9-week treatment duration. Changes in weight will be measured. The study is currently on-going at two study centers in Australia and is fully enrolled. Top-line data from the study is anticipated to be available in mid-2025. Vivani has successfully utilized research and development rebates from the Australian government for relevant 2024 expenses to defray a portion of the costs from this clinical trial and anticipates being able to utilize similar rebates going forward. Since clinical studies conducted in Australia comply with the International Conference on Harmonization guidelines, data generated in Australia generally are acceptable to the U.S. Food and Drug Administration and other regulatory authorities. Vivani anticipates use of relevant clinical data generated in Australia to support regulatory submissions in other geographies including the United States. Additional guidance regarding future regulatory submissions will be provided as new information becomes available. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Vivani’s emerging pipeline includes NPM-139 (semaglutide implant) which is also under development for chronic weight management. The semaglutide implant is being initially developed as a twice-yearly implant but it has the added potential benefit of once-yearly administration. NPM-119 refers to the Company’s six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason why obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments, face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers. For more information, please visit www.vivani.com. The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

13 Mar 2025

·www.pharmaceutical-technology.com

Vivani treats first patient with long-lasting drug implant for weight loss

The device, dubbed NPM-115, is a miniature sub-dermal implant that delivers exenatide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). Image credit: Shutterstock / Formatoriginal. A day after announcing a business split-off to focus on weight loss and diabetes implants, Vivani Medical has implanted the first patient with its device. The procedure is part of a first-in-human clinical trial in Australia called LIBERATE-1 (NCT05670379) evaluating the implant in obese or overweight individuals. The company’s other implant called NPM-119 is being developed for type 2 diabetes treatment. Shares in the Nasdaq-listed company rose by 5% at market open compared to a pre-announcement market close. Shares in Vivani were already elevated after it revealed plans yesterday to spin-off its neurostimulation business Cortigent as a publicly traded company. The move is expected to facilitate both companies prioritising their respective product pipelines. The NPM-115 device is a miniature sub-dermal implant that delivers exenatide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). Vivani says the drug has demonstrated good drug release both in vitro and in animal models. The implant is designed to last for six months. The LIBERATE-1 study, which Vivani also revealed is now fully enrolled, is investigating NPM-115’s safety, tolerability, and full pharmacokinetic profile in obese or overweight subjects. Participants will first be given injections of Novo Nordisk’s popular GLP-1RA medication Wegovy (semaglutide) for two months, then one of three treatments – Vivani’s implant, weekly injections of AstraZeneca’s branded exenatide medication for diabetes Bydureon BCise, or weekly Wegovy doses. Vivani will assess changes in weight through a nine-week duration, with top-line data slated to be available in mid-2025. GLP-1RAs have become one of the dominant forces in the pharmaceutical sector. Wegovy is forecast to generate sales of $19.4bn by 2030, according to analysis by GlobalData. Eli Lilly’s rival compound Zepbound (tirzepatide), which has demonstrated slightly better efficacy, is predicted to go even further , seeing sales of $25.2bn by the same year. Whilst their use has skyrocketed amongst overweight patients, the necessity for regular injections has been a source of adherence issues. A real-world study on just under 4,800 patients on GLP-1RA medication found that around half were non-adherent. Vivani believes its long-lasting drug candidate could provide an alternative option that improves medication adherence and reduces administration burden. Vivani’s CEO Adam Mendelsohn said: “About half of people regularly miss doses as indicated by real-world medication adherence data. “Missed doses not only lead to suboptimal efficacy but can also exacerbate tolerability issues. We believe our miniature, ultra long-acting implants, designed to improve medication adherence, have the potential to improve efficacy and minimise tolerability issues.”

27 Feb 2025

·firstwordpharma.com

Medicare spending on popular diabetes meds jumps over 350% in five years

Medicare Part D spending on leading diabetes medications has reached unprecedented levels, with expenditure skyrocketing from $7.7 billion in 2019 to $35.8 billion in 2023 — translating to a 364% increase over the five-year period, according to newly released data.Auditors from the US Department of Health and Human Services' Office of Inspector General (OIG) identified and analysed Medicare Part D data for 10 widely prescribed type 2 diabetes medications, comprising seven GLP-1s and three SGLT-2 inhibitors, across the US and five overseas territories between January 2019 and December 2023. The analysis looked at utilisation metrics and spending patterns, drawing comparisons with metformin as a baseline therapy. GLP-1s lead uptickDuring the audit period, Medicare Part D expenditure for selected drugs totalled $92.8 billion, with six medications exhibiting substantial spending increases, led by GLP-1 products. Spending on Novo Nordisk's Rybelsus (semaglutide) jumped from $366,000 in 2019 to approximately $1.7 billion by 2023 — a 2182% increase — whereas Ozempic (semaglutide) expenditures increased nearly 16-fold from $552 million to $9.2 billion over the same period, with the number of beneficiaries receiving the medication rising by 929%. Meanwhile, Eli Lilly's Mounjaro (tirzepatide) showed 1541% spending growth in just its second year of coverage.The OIG noted that given a number of the medicines are commonly used off-label for other conditions, notably obesity, their increased use warrants "further inquiry to determine whether…the associated drugs were utilised for medically accepted indications." Meanwhile, TD Cowen analyst Rick Weissenstein suggested that "the data brief may provide ammunition for HHS Secretary Robert Kennedy Jr. and others who see the surge in GLP-1 use as a symptom of 'overmedication' more generally in the US."In contrast, use and spending on Novo's Victoza (liraglutide), Johnson & Johnson's Invokana (canagliflozin), as well as AstraZeneca's Byetta (exenatide) and Bydureon (exenatide extended-release), declined from 2019 to 2023, likely due to the introduction of newer alternatives. In addition, metformin expenditure decreased by 5% from $661 million in 2019 to $628 million in 2023.Spending growth outpaces enrolmentAccording to the analysis, the growth of the selected medications significantly outpaced the 12% increase in Medicare Part D enrolment during the same timeframe, raising concerns about the long-term financial sustainability of the programme. The report suggests that even if spending grows at the minimum observed annual rate of 42% during the five-year period, it could exceed $102 billion for the 10 drugs in 2026. “This substantial increase could have a financial impact on the Medicare programme,” the auditors noted in the report, adding that these findings “may be beneficial to CMS and other policymakers when developing future programme guidance related to these drugs.”Both Ozempic and Rybelsus made it on to the expanded list of medicines selected for the second round of Medicare price negotiations, drawn up by the outgoing Biden administration last month.

100 Deals associated with Exenatide

External Link

KEGG	Wiki	ATC	Drug Bank
D04121	Exenatide	A10BJ01	DB01276

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	AstraZeneca AB	28 Apr 2005

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pseudotumor Cerebri	Phase 3	United States	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	Australia	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	Germany	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	Israel	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	New Zealand	Invex Therapeutics Ltd.	18 Nov 2022
Pseudotumor Cerebri	Phase 3	United Kingdom	Invex Therapeutics Ltd.	18 Nov 2022
Diabetes Mellitus, Type 1	Phase 3	Netherlands	AstraZeneca PLC	21 Feb 2017
Obesity	Phase 3	United States	AstraZeneca PLC	22 Mar 2016
Polycystic Ovary Syndrome	Phase 3	United States	AstraZeneca PLC	22 Mar 2016
Heart Failure	Phase 3	France	Eli Lilly & Co.	01 May 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00845507 (Exenatide for the Treatment of Weight Gain Associated with Olanzapine in Obese Adults, Pubmed \| J Affect Disord)	Phase 4	Weight Gain	-	Exenatide	cviruukoff(mweaphaazf) = The most common side effects in the exenatide group were gastrointestinal symptoms fuomccnafs (gqcugyyohd ) View more	Positive	01 Apr 2025
				Placebo
NCT04232969 (Pubmed) Manual	Phase 3	Parkinson Disease	194	exenatide	vuzegirzob(xeaprocncl) = lfalejkeeb clymoyjfgp (qmwskbshyh, 11.2) View more	Negative	04 Feb 2025
				placebo	vuzegirzob(xeaprocncl) = fdawzxmqqn clymoyjfgp (qmwskbshyh, 11.4) View more
NCT01107717 (EDICT, CTgov)	Phase 4	Diabetes Mellitus, Type 2	318	exenatide+pioglitazone+metformin (Triple Therapy)	lbczskdekf(npmrraqpux) = dyizowsvww wfehnzhdpb (ohudoruyfk, 0.1) View more	-	05 Sep 2024
				glargine+metformin+glyburide (Conventional Therapy)	lbczskdekf(npmrraqpux) = tibnxfsjyj wfehnzhdpb (ohudoruyfk, 0.1) View more
T1D Exchange Online Registry (ADA2024)	Not Applicable	Diabetes Mellitus, Type 1	-	GLP-1	ouwxdbdota(lktpnpvvpj) = duibenajpm wvfkbzbdqb (lsxsvosavz )	Positive	14 Jun 2024
ENDO (ENDO2024)	Not Applicable	Hypothalamic obesity	-	Liraglutide 0.6 mg daily	alujapbiyb(xyopdxmhzo) = yzeelcidzu daxuyhmapm (rrgltodnhx ) View more	Positive	01 Jun 2024
				Insulin degludec	ukwktxbufz(cctzuwydck) = yfzuylxpoz vysezzexqn (zqsmegmzni ) View more
NCT03029351 (1981, CTgov)	Phase 4	Kidney Diseases \| Diabetes Mellitus, Type 2 \| Proteinuria	15	Exenatide Extended Release for Inj Susp 2 MG (Exenatide Extended Release)	gbpqrxnevl(qxsypqsiky) = onwdxlasff zefcnbvfty (npamaioccs, 122) View more	-	16 Apr 2024
				Placebo (Placebo)	gbpqrxnevl(qxsypqsiky) = uriudmijro zefcnbvfty (npamaioccs, 132) View more
NCT02962492 (CTgov)	Not Applicable	Diabetes Mellitus, Type 1	70	Placebo (Placebo Arm:)	gjzcwtmzds(sqmtvsknpp) = fbeqflzzvm dtphjszpbq (qfcvoaoksa, 0.17) View more	-	29 Feb 2024
				Dapagliflozin (Dapagliflozin Arm:)	gjzcwtmzds(sqmtvsknpp) = ilealliwux dtphjszpbq (qfcvoaoksa, 0.22) View more
NCT01524705 (FLAT-SUGAR, CTgov)	Phase 4	Diabetes Mellitus, Type 2	102	Insulin Glargine+Metformin+Exenatide	qfnfydjizr(jcvpgroazb) = phnkibxunw swtyvjgxhj (wtxvidaydx, 7.89) View more	-	29 Dec 2023
NCT04307797 (EASD2023)	Phase 4	Diabetes Mellitus, Type 2	8	Saline	hprnjvlhac(sqkencnynp) = There were no adverse events intufyinwp (cbozhkppil ) View more	Negative	04 Oct 2023
				Glucagon
ACTRN12619000497101 (ACTRN, EASD2023)	Phase 2	Diabetes Mellitus, Type 2	32	Exenatide once-weekly (QW)	wnoufvsxra(efrbmhtlya) = cdekmumvor opdqdalhlc (kurlcgoycb, 1.7)	Positive	04 Oct 2023
				Placebo	wnoufvsxra(efrbmhtlya) = euwqnktaia opdqdalhlc (kurlcgoycb, 2.1)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis